YH 14618

Drug Profile

YH 14618

Alternative Names: P2K; Peniel 2K; Peniel-2000; YH14618

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ensol Biosciences
  • Developer Yuhan
  • Class Peptides
  • Mechanism of Action Transforming growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intervertebral disc degeneration

Most Recent Events

  • 06 Sep 2017 YH 14617 is still in phase II development for Intervertebral disc degeneration in South Korea (Yuhan Corporation pipeline, September 2017)
  • 01 Aug 2016 Yuhan Corporation completes a phase IIb trial for Intervertebral disc degeneration in South Korea (NCT02320019)
  • 01 Mar 2015 Phase-II clinical trials in Intervertebral disc degeneration in South Korea (Intra-articular) (NCT02320019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top